Sfoglia per AUTORE
MASINI C
Collezione AOU Novara

  

Items : 7

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.

2021
AO Cuneo
ASL Asti
ASL Biella
ASL Cuneo 2
AOU Città della Salute di Torino
ASL Città di Torino
AOU Novara

Tucci M; Baier S; Gennari A; Bellissimo AR; Ciccone G; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Bianchi S; Mosca A; Dalla Volta A; Prati V; Dal Canton O; Berruti A;

GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. in Therapeutic advances in urology / Ther Adv Urol. 2021 Oct 22;13:17562872211054302. doi: 10.1177/17562872211054302. eCollection 2021 Ja

2021
ASL Vercelli
AOU Novara

La Torre L; Baldessari C; Gernone A; Dalla Volta A; Toscani I; Zucali PA; Corti F; Fanelli M; Stellato M; Morelli F; Mucciarini C; Galli L; Macrini S; Atzori F; Gatti A; Caffo O; Fornarini G; Vitale MG; Massari F; Masini C; Cattrini C; Cortellini A; Rizzo M; Buti S; Bersanelli M; Zara D; Gennari A; Bracarda S; Procopio G; et alii...

The effect of a treatment delay on outcome in metastatic renal cell carcinoma. in Urologic oncology / Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29.

2019
AOU Novara

Iacovelli R; Galli L; De Giorgi U; Porta C; Nolè F; Zucali P; Sabbatini R; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Buti S; Massari F; Masini C; Ricotta R; Biasco E; Lolli C; Gri N; Verri E; Miggiano C; Vitale MG; Tortora G;

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7.

2018
AOU Novara

Iacovelli R; De Giorgi U; Galli L; Zucali P; Nolè F; Sabbatini R; Fraccon AP; Basso U; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Pasini F; Masini C; Massari F; Buti S; Sava T; Sacco C; Ricotta R; Sperduti I; Tortora G; Porta C;

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. in Anticancer research / Anticancer Res. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticanres.12807.

2018
AOU Novara

Sbrana A; Biasco E; Paolieri F; Palesandro E; Caserta C; Iacovelli R; Detti B; Santini D; Mosca A; Morelli F; Fornarini G; De Giorgi U; Masini C; Galli L;

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. in Urologic oncology / Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29.

2017
AOU Novara

Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G;

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. in The Journal of urology / J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18.

2015
AOU Novara

Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; et alii...